



**Ziyuanyuan Holdings Group Limited**

**紫元元控股集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 8223)**

**FIRST QUARTERLY RESULTS ANNOUNCEMENT  
FOR THE THREE MONTHS ENDED 31 MARCH 2022**

**CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG  
LIMITED (THE “STOCK EXCHANGE”)**

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

*Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement, for which the directors (the “**Directors**”) of Ziyuanyuan Holdings Group Limited (the “**Company**”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

The board of Directors (the “**Board**”) hereby announces the unaudited condensed consolidated financial results of the Company and its subsidiaries (the “**Group**”) for the three months ended 31 March 2022, together with the comparative unaudited figures for the corresponding period in 2021, as follows:

## UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

*For the three months ended 31 March 2022*

		Three months ended 31 March	
		2022	2021
	Notes	RMB'000 (Unaudited)	RMB'000 (Unaudited)
Revenue			
Finance leasing income		11,271	12,863
Interest income from loan receivables		502	290
Income from postpartum care services		11,869	9,400
Income from trading of medical equipment and consumables		8,111	—
Total revenue	3	31,753	22,553
Cost of sales		(6,611)	—
Bank interest income		34	96
Other gains and losses	4	1,209	1,338
Staff costs	8	(10,136)	(7,597)
Reversal of impairment losses/(impairment losses) under expected credit loss (“ECL”) model, net	5	1,100	(254)
Other operating expenses		(12,031)	(10,503)
Finance costs	6	(3,186)	(2,041)
Profit before income tax		2,132	3,592
Income tax expenses	7	(237)	(521)
Profit and total comprehensive income for the period	8	1,895	3,071
Profit and total comprehensive income for the period attributable to:			
Owners of the Company		2,155	3,011
Non-controlling interests		(260)	60
		1,895	3,071
Earnings per share for profit attributable to owners of the Company during the period			
– Basic and diluted ( <i>RMB cents</i> )	10	0.54	0.75

# UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the three months ended 31 March 2022

	Attributable to owners of the Company						Non-controlling interests	Total
	Share capital	Share premium	Capital and other reserves	Statutory reserves	Retained profits	Total		
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
At 1 January 2022 (audited)	33,839	65,218	133,023	9,411	58,032	299,523	4,799	304,322
Profit and total comprehensive income for the period	—	—	—	—	2,155	2,155	(260)	1,895
At 31 March 2022 (unaudited)	<u>33,839</u>	<u>65,218</u>	<u>133,023</u>	<u>9,411</u>	<u>60,187</u>	<u>301,678</u>	<u>4,539</u>	<u>306,217</u>
At 1 January 2021 (audited)	33,839	73,551	133,023	8,817	53,138	302,368	944	303,312
Profit and total comprehensive income for the period	—	—	—	—	3,011	3,011	60	3,071
Acquisition of subsidiaries	—	—	—	—	—	—	3,254	3,254
At 31 March 2021 (unaudited)	<u>33,839</u>	<u>73,551</u>	<u>133,023</u>	<u>8,817</u>	<u>56,149</u>	<u>305,379</u>	<u>4,258</u>	<u>309,637</u>

# NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 1. BASIS OF PREPARATION

The unaudited condensed consolidated financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards (“**HKFRSs**”) issued by the Hong Kong Institute of Certified Public Accountants (the “**HKICPA**”) as well as with the applicable disclosure requirements of Chapter 18 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited.

## 2. PRINCIPAL ACCOUNTING POLICIES

The unaudited condensed consolidated financial statements have been prepared under historical cost convention, except for certain financial instruments, which are stated at fair value.

The preparation of the unaudited consolidated financial results in conformity with HKFRSs requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group’s accounting policies. Except as described below, the accounting policies used in the preparation of these unaudited condensed consolidated financial statements for the three months ended 31 March 2022 are consistent with those followed in the preparation of the Group’s annual audited financial statements for the year ended 31 December 2021.

### **Application of new and amendments to HKFRSs**

In the current period, the Group has applied the new and amendments to HKFRSs issued by the HKICPA which are effective for the annual period beginning on or after 1 January 2022 for the preparation of the Group’s unaudited condensed consolidated financial statements.

The application of new and amendments to HKFRSs in the current period has no material impact on the amounts reported and/or disclosures set out in these unaudited condensed consolidated financial statements.

### 3. REVENUE

Revenue for the period represents finance leasing income, interest income on loan receivables, income from postpartum care services and income from trading of medical equipment and consumables in the PRC. The amounts of each significant category of revenue recognised in revenue during the period are as follows:

	<b>Three months ended 31 March</b>	
	<b>2022</b>	<b>2021</b>
	<b>RMB'000</b>	<b>RMB'000</b>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
Finance leasing income	11,271	12,863
Interest income from loan receivables	502	290
Income from postpartum care services	11,869	9,400
Income from trading of medical equipment and consumables	8,111	–
	<u>31,753</u>	<u>22,553</u>

### 4. OTHER GAINS AND LOSSES

	<b>Three months ended 31 March</b>	
	<b>2022</b>	<b>2021</b>
	<b>RMB'000</b>	<b>RMB'000</b>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
Fair value gain on financial assets at fair value through profit or loss	1,020	556
Government subsidies ( <i>Note</i> )	240	729
Exchange (loss)/gain, net	(55)	3
Others	4	50
	<u>1,209</u>	<u>1,338</u>

*Note:*

The PRC tax authority has announced that for the years ended 31 December 2021 and 31 December 2022, entities engaged in provision of service in four particular areas could have extra deduction on VAT.

### 5. (REVERSAL OF IMPAIRMENT LOSSES)/IMPAIRMENT LOSSES UNDER ECL MODEL, NET

	<b>Three months ended 31 March</b>	
	<b>2022</b>	<b>2021</b>
	<b>RMB'000</b>	<b>RMB'000</b>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
(Reversal of impairment losses)/impairment losses recognised on:		
– finance lease receivables	(1,097)	296
– loan receivables	(3)	(42)
	<u>(1,100)</u>	<u>254</u>

## 6. FINANCE COSTS

	Three months ended 31 March	
	2022	2021
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
Imputed interests on interest-free deposits from finance lease customers	48	289
Interests on bank and other borrowings	2,965	1,411
Interests on lease liabilities	173	341
	<u>3,186</u>	<u>2,041</u>

## 7. INCOME TAX EXPENSES

	Three months ended 31 March	
	2022	2021
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
The charge comprises:		
Current tax		
– PRC Enterprise Income Tax	213	35
Deferred tax	24	486
	<u>237</u>	<u>521</u>

No provision for taxation in Hong Kong has been made as the Group's income neither arises in, nor is derived from, Hong Kong.

Under the Law of PRC on Enterprise Income Tax (the “EIT Law”) and the Implementation Regulation of the EIT Law, the tax rate of the PRC subsidiaries is 25% for both periods, except for one subsidiary of the Group which is recognised as high technology enterprise is entitled to enjoy a preferential tax rate of 15%.

According to the EIT Law and the Implementation of the EIT Law of the PRC, certain PRC subsidiaries of the Group qualified as small low profit enterprises with annual taxable income not more than RMB1,000,000, and the portion that exceeds RMB1,000,000 but does not exceed RMB3,000,000 (inclusive) are entitled to enterprise income tax calculated at 12.5% and 50% of its taxable income at a tax rate of 20%, respectively.

## 8. PROFIT FOR THE PERIOD

Profit for the period is arrived at after charging:

	<b>Three months ended 31 March</b>	
	<b>2022</b>	<b>2021</b>
	<b><i>RMB'000</i></b>	<b><i>RMB'000</i></b>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
Directors' emoluments	<b>726</b>	436
Other staff costs		
– Salaries, allowances and other staff benefits	<b>8,973</b>	6,640
– Staffs' retirement benefit scheme contributions	<b>1,560</b>	978
	<hr/>	<hr/>
Total staff costs	<b>11,259</b>	8,054
	<hr/>	<hr/>
<i>Less: staff costs recognised as research and development costs</i>	<b>(1,123)</b>	(457)
	<hr/>	<hr/>
Staff costs recognised in profit or loss	<b>10,136</b>	7,597
	<hr/>	<hr/>
Amortisation of intangible assets	<b>255</b>	258
Cost of inventories sold	<b>6,611</b>	–
Depreciation of property, plant and equipment	<b>934</b>	1,228
Depreciation of right-of-use assets	<b>2,322</b>	2,474
Research and development costs recognised as an expense (included in other operating expenses)	<b>123</b>	472
Short-term leases payments	<b>1,411</b>	1,323
	<hr/> <hr/>	<hr/> <hr/>

## 9. DIVIDENDS

The board of Directors of the Company does not recommend the payment of an interim dividend in respect of the three months ended 31 March 2022 (three months ended 31 March 2021: Nil).

## 10. EARNINGS PER SHARE

The calculation of basic earnings per share is based on the profit attributable to owners of the Company of approximately RMB2,155,000 (three months ended 31 March 2021: RMB3,011,000) and on the weighted average number of ordinary shares in issue during the period of 400,000,000 (three months ended 31 March 2021: 400,000,000).

Diluted earnings per share is the same as basic earnings per share as there was no potential dilutive ordinary share in issue during both periods.

## **MANAGEMENT DISCUSSION AND ANALYSIS**

The Board of Directors of the Company announces the unaudited condensed consolidated quarterly results of the Group for the three months ended 31 March 2022 together with the corresponding comparative figures.

### **BUSINESS REVIEW**

For the three months ended 31 March 2022, the Group is principally engaged in provision of medical equipment finance leasing services, maternal and child postpartum care industry services and trading of medical equipments and consumables business in the PRC.

#### **Finance leasing services**

The Group has been focusing on provision of finance leasing services to SMEs customers in the medical equipment industry in various provinces, municipalities, and autonomous regions in the PRC, where the Group has established connections with industry players and gained operational expertise. The finance lease offered by the Group comprises direct finance leasing and sale-leaseback. The Group provided services to approximately 3,390 SMEs customers across 30 provinces, municipalities and autonomous regions in the PRC as at 31 March 2022. The Group derived a revenue of RMB11.8 million from the finance leasing services for the three months ended 31 March 2022.

#### **Maternal and child postpartum care industry services**

Postpartum confinement (坐月) is a traditional Chinese custom, which allows women to rest fully after giving birth, and to recover through diet. It is said that it is the best time for women to improve their physical well-being. Hence, centres for the provision of postpartum care services (月子中心) had emerged.

The Group provided postpartum care services, consisting of four major areas of (i) health care for postpartum mothers and newborn babies; (ii) dietary and nutrition for postpartum mothers; (iii) recovery and beauty for postpartum mothers; and (iv) intellectual development for newborn babies. The Group derived a revenue of RMB11.9 million from the maternal and child postpartum care industry services for the three months ended 31 March 2022.

#### **Trading of medical equipments and consumables business**

The Group is engaged in the trading of medical equipments and consumables in the PRC. The Group derived a revenue of RMB8.1 million from trading of medical equipments and consumables business for the three months ended 31 March 2022.



## **OUTLOOK**

The Group is still reasonably optimistic to sustain the core business given all the economic uncertainties with the outbreak of Covid-19. The Group will continue to seek for the best possible opportunities to grow the Group's business by leveraging current client base. After the pandemic, the healthcare industry will be a new economic breakthrough with significant value-added potentials. The Group initiated pre-emptive deployment of finance leasing service and medical equipment fields that focus on oral cavity and maternity and child industry. Meanwhile, the Group developed trading of medical equipments and consumables business, which cooperates with the maternal and child postpartum care industry, in order to capture pioneer opportunities and support the industrial upgrade of the healthcare industry, diversifying the income of the Group.

In 2022, the global economic situation remains grim. We will continue to increase investment in various businesses and continue to strive to find opportunities in the face of challenges, so as to return shareholders and the public, and realize corporate value as well as social value.

## **FINANCIAL REVIEW**

### **Revenue**

Revenue consists of (i) finance leasing income and interest income from loan receivables in finance leasing services; (ii) postpartum care services income; and (iii) income from trading of medical equipments and consumables. For the three months ended 31 March 2022, the Group's revenue increased by approximately RMB9.2 million or approximately 40.8% to approximately RMB31.8 million (three months ended 31 March 2021: approximately RMB22.6 million). The increase in revenue for the three months ended 31 March 2022 was mainly attributable to (i) postpartum care services income increased from approximately RMB9.4 million for the three months ended 31 March 2021 to approximately RMB11.9 million for the three months ended 31 March 2022; and (ii) income from trading of medical equipments and consumables of approximately RMB8.1 million (three months ended 31 March 2021: Nil), which offsetting the finance leasing income decreased from approximately RMB13.2 million for the three months ended 31 March 2021 to approximately RMB11.8 million for the three months ended 31 March 2022.

### **Cost of sales**

Cost of sales represents the cost of medical equipments and consumables sold during the period.

### **Staff cost**

Staff costs include primarily Directors' remuneration, employee salaries, allowances and other staff benefits as well as employee retirement benefits scheme contributions. Staff costs increased from RMB7.6 million for the three months ended 31 March 2021 to approximately RMB10.1 million for the three months ended 31 March 2022. The increase was mainly attributable to (i) the increase in head count and staff salaries for existing staff; and (ii) the staff costs incurred by postpartum care services business increased from approximately RMB3.0 million for the three months ended 31 March 2021 to approximately RMB4.4 million for the three months ended 31 March 2022.

## **(Reversal of impairment losses)/impairment losses under expected credit loss (“ECL”) model, net**

The Group is not required to provide general provisions as commercial banks and other financial institutions which the China Banking Regulatory Commission regulates. The provisioning policies are based on the applicable accounting standards. The management assesses the measurement of ECL in relation to finance lease receivables and loan receivables. In determining the impairment of finance lease receivables and loan receivables, the management considers shared credit risk characteristics including industry types, historical past due information and lessees’ creditworthiness for grouping, and assesses credit losses based on internal credit rating and on a forward looking basis with the use of appropriate models and assumptions relate to the economic inputs and the future macroeconomic conditions in accordance with Hong Kong Financial Reporting Standard 9.

For the three months ended 31 March 2022, reversal of impairment loss of approximately RMB1.1 million (three months ended 31 March 2021: impairment loss of RMB0.3 million) was recognised. The reversal of impairment losses recognised in current period was mainly due to the decrease in total finance lease receivables.

## **Other operating expenses**

Other operating expenses include primarily travelling expenses, depreciation of property, plant and equipment, depreciation of right-of-use assets, short-term leases payments and the operating expenses incurred by maternal and child postpartum care business. Other operating expenses increased from approximately RMB10.5 million for the three months ended 31 March 2021 to approximately RMB12.0 million for the three months ended 31 March 2022. The increase was mainly due to the increase in other operating expenses of the postpartum care business offsetting the decrease in other operating expenses of the finance leasing business.

The other operating expenses for the postpartum care business increased from approximately RMB5.8 million for the three months ended 31 March 2021 to approximately RMB8.5 million for the three months ended 31 March 2022, it was mainly attributable to (i) the miscellaneous expenses of postpartum care business increased from approximately RMB2.3 million for the three months ended 31 March 2021 to approximately RMB3.2 million for the three months ended 31 March 2022; (ii) depreciation of right-of-use assets increased from approximately RMB1.5 million for the three months ended 31 March 2021 to approximately RMB2.0 million for the three months ended 31 March 2022; (iii) short-term leases payments increased from approximately RMB0.9 million for the three months ended 31 March 2021 to approximately RMB1.4 million for the three months ended 31 March 2022; and (iv) office expenses, water, electricity and property management fees increased from approximately RMB0.4 million for the three months ended 31 March 2021 to approximately RMB0.8 million for the three months ended 31 March 2022.

The other operating expenses for finance leasing business decreased from approximately RMB4.7 million for the three months ended 31 March 2021 to approximately RMB3.5 million for the three months ended 31 March 2022. The decrease was mainly attributed to (i) depreciation of property, plant and equipment decreased from approximately RMB0.9 million for the three months ended 31 March 2021 to approximately RMB0.3 million for the three months ended 31 March 2022; and (ii) due to the impact of Covid-19, travelling expenses decreased from approximately RMB1.0 million for the three months ended 31 March 2021 to approximately RMB0.4 million for the three months ended 31 March 2022.

### **Finance costs**

Finance costs consist of (i) imputed interest expense on interest-free deposits from finance lease customers; (ii) interest on bank borrowing; and (iii) interests on lease liabilities. Finance costs increased from approximately RMB2.0 million for the three months ended 31 March 2021 to approximately RMB3.2 million for the three months ended 31 March 2022. The increase was mainly due to the interest on bank borrowing increased from approximately RMB1.4 million for the three months ended 31 March 2021 to approximately RMB3.0 million for the three months ended 31 March 2022.

### **Income tax expenses**

Certain PRC subsidiaries of the Group qualified as small low-profit enterprises with annual taxable income not more than RMB1.0 million, and the portion that exceeds RMB1.0 million but does not exceed RMB3.0 million (inclusive) are entitled to enterprise income tax calculated at 12.5% and 50% of its taxable income at a tax rate of 20%, respectively. A PRC subsidiary of the Group recognised as high technology enterprise is entitled to a preferential enterprise income tax rate of 15%. The enterprise income tax rate applicable to the other PRC subsidiaries of the Group is 25%.

### **Profit and total comprehensive income attributable to owners of the Company**

For the three months ended 31 March 2022 and 2021, the Group's profit and total comprehensive income attributable to owners of the Company was approximately RMB2.2 million and RMB3.0 million, respectively. The decrease of profit and total comprehensive income attributable to owners of the Company for the three months ended 31 March 2022 was mainly attributable to the increase in staff costs, other operating expenses and finance costs which offsetting the increase in revenue and reversal of impairment losses under ECL model, net as compared to the corresponding period in 2021.

## **Dividend**

The Board of Directors of the Company does not recommend the payment of an interim dividend in respect of the three months ended 31 March 2022 (three months ended 31 March 2021: Nil).

## **CAPITAL STRUCTURE**

The shares of the Company (the “**Shares**”) were successfully listed on the GEM of the Stock Exchange on 9 July 2018. There has been no change in the capital structure of the Group since then. The share capital of the Group only comprises ordinary Shares.

As at 31 March 2022, the Company’s issued share capital was HK\$40,000,000 and the number of its issued ordinary Shares was 400,000,000 of HK\$0.1 each.

## **COMPETING INTEREST**

For the three months ended 31 March 2022, none of the Directors or the controlling shareholders of the Company or their respective close associates (as defined in the GEM Listing Rules) is interested in any business which competes or is likely to compete, either directly or indirectly, with the business of the Group or has any conflicts of interest with the Group.

## **DEED OF NON-COMPETITION**

The controlling shareholders of the Company, namely Mr. Zhang Junshen (through Hero Global Limited), Mr. Zhang Junwei (through Icon Global Holding Limited), (the “**Controlling Shareholders**”) entered into a deed of non-competition dated 12 June 2018 (“**Deed of Non-competition**”) in favour of the Company (for itself and as trustee for each of its subsidiaries). For details of the Deed of Non-competition, please refer to the section headed “Relationship with Controlling Shareholders – Non-competition Undertaking” in the Prospectus. Each of the Controlling Shareholders has confirmed that none of them is engaged in, or interested in any business (other than the Group) which, directly or indirectly, competes or may compete with the business of the Group.

The independent non-executive Directors have also reviewed the status of compliance and confirmed that all the undertakings under the Deed of Non-competition have been complied with by each of the Controlling Shareholders during the period and up to the date of this announcement.

## **PURCHASE, SALES OR REDEMPTION OF THE COMPANY’S LISTED SECURITIES**

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company’s listed securities during the period and up to the date of this announcement.

## **CORPORATE GOVERNANCE PRACTICES**

The Company considers the maintenance of a high standard of corporate governance important to the continuous growth of the Group. The Company’s corporate governance practices are based on code provisions as set out in the Corporate Governance Code (the “**CG Code**”) as contained in Appendix 15 of the GEM Listing Rules. Other than the deviation from code provision A.2.1, the Company has adopted and complied with, where applicable, the CG Code to ensure that the Group’s business activities and decision-making processes are regulated in a proper and prudent manner.

Up to the date of this announcement, other than the deviation from code provision A.2.1, the Company complied with the provisions of the CG Code as set out in Appendix 15 to the GEM Listing Rules.

### **CODE PROVISION A.2.1**

In accordance with the code provision A.2.1 of the CG Code, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. The Board is of the view that although Mr. Zhang Junshen is the chairman and the chief executive officer of the Company, this structure will not impair the balance of power and authority between the Board and the management of the Company. The balance of power and authority is ensured by the operations of the Board, which comprises experienced and high caliber individuals and meets regularly to discuss issues affecting operations of the Company. The Board believes that this structure is conducive to strong and consistent leadership, enabling the Group to make and implement decisions promptly and efficiently. The Board has full confidence in Mr. Zhang Junshen and believes that his appointment to the posts of chairman and chief executive officer is beneficial to the business prospects of the Company.

## **EVENT AFTER THE REPORTING PERIOD**

The Directors are not aware of any significant event which had material effect on the Group subsequent to 31 March 2022 and up to the date of this announcement.

## SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted Rules 5.48 to 5.67 of the GEM Listing Rules as its own code of conduct (“**Code of Conduct**”) regarding securities transactions by the Directors. The Company has confirmed, having made specific enquiry of the Directors, that all the Directors have complied with the Code of Conduct for the three months ended 31 March 2022 and up to date of this announcement.

## AUDIT COMMITTEE AND REVIEW OF QUARTERLY RESULTS

The Group has established an audit committee (the “**Audit Committee**”) pursuant to a resolution of the Directors passed on 12 June 2018 in compliance with Rules 5.28 to 5.33 of the GEM Listing Rules and with written terms of reference in compliance with the CG Code.

The Audit Committee currently consists of our non-executive Director, namely Mr. Lyu Di and two of our independent non-executive Directors, namely Mr. Chan Chi Fung Leo and Dr. Deng Bin. Mr. Chan Chi Fung Leo currently serves as the chairman of the Audit Committee, who holds the appropriate professional qualifications as required under Rules 5.05(2) and 5.28 of the GEM Listing Rules.

The financial information in this announcement has not been audited. The Audit Committee has reviewed the unaudited condensed consolidated financial statements of the Group for the three months ended 31 March 2022 and is of the opinion that the preparation of such statements complied with the applicable accounting standards, the requirements under the GEM Listing Rules and other applicable legal requirements, and that adequate disclosures had been made.

By order of the Board  
**Ziyuanyuan Holdings Group Limited**  
**Zhang Junshen**  
*Chairman and Chief Executive Officer*

Hong Kong, 13 May 2022

*As at the date of this announcement, the executive Directors are Mr. Zhang Junshen (Chairman and Chief Executive Officer) and Mr. Zhang Yong, the non-executive Director is Mr. Lyu Di, and the independent non-executive Directors are Mr. Chan Chi Fung Leo, Mr. Chow Siu Hang and Dr. Deng Bin.*

*This announcement will remain on the “Latest Company Announcements” page of the GEM website at [www.hkgem.com](http://www.hkgem.com) for at least 7 days from the date of its posting and on the website of the Company at [www.ziyygroup.com](http://www.ziyygroup.com).*